Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Neuroimaging study of the effects of phospholipase A2 (PLA2) inhibition on brain metabolism and neuroinflammation in a rat model of Alzheimer’s Disease.

FY 2022-23

Summary
Alzheimer’s is a devastating brain disorder which does not have a cure. However, the protein phospholipase A2 (PLA2) offers a potential therapeutic target. PLA2 has been linked to many known hallmarks of Alzheimer’s disease through the release of fats from the cell membrane of brain cells. In excess, these fats can wreak havoc on the brain. They increase inflammation which in turn may cause the accumulation of abnormal proteins. In addition, they cause the release of toxic compounds and impact memory formation, both of which are associated with brain degeneration and memory impairment. Therefore, it is important to understand how PLA2 impacts each hallmark of Alzheimer’s disease (memory impairment, inflammation, and abnormal protein accumulation) simultaneously. This will give a clearer picture on how PLA2 influences Alzheimer’s progression. To study this, we will inhibit PLA2 activity in a rat model of Alzheimer’s and observe the effects on each hallmark of Alzheimer’s disease. We will be using a magnetic resonance imaging (MRI) technique which enables the observation of some of the hallmarks non-invasively. This is important as we may gain insight into markers of Alzheimer’s disease which could be used to diagnosis and monitor disease progression. Overall, I aim to better understand the role of PLA2 in Alzheimer’s disease progression, if PLA2 activity corresponds to any key markers of disease, and if PLA2 inhibition could be therapeutic.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
486273
Name
Hiles Emily G
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Neuroimaging study of the effects of phospholipase A2 (PLA2) inhibition on brain metabolism and neuroinflammation in a rat model of Alzheimer’s Disease.
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Aging; Alzheimer'S Disease; Behaviour; Metabolism; Neurochemistry; Neuroimaging; Neuroinflammation
Abstract
Alzheimer’s is a devastating brain disorder which does not have a cure. However, the protein phospholipase A2 (PLA2) offers a potential therapeutic target. PLA2 has been linked to many known hallmarks of Alzheimer’s disease through the release of fats from the cell membrane of brain cells. In excess, these fats can wreak havoc on the brain. They increase inflammation which in turn may cause the accumulation of abnormal proteins. In addition, they cause the release of toxic compounds and impact memory formation, both of which are associated with brain degeneration and memory impairment. Therefore, it is important to understand how PLA2 impacts each hallmark of Alzheimer’s disease (memory impairment, inflammation, and abnormal protein accumulation) simultaneously. This will give a clearer picture on how PLA2 influences Alzheimer’s progression. To study this, we will inhibit PLA2 activity in a rat model of Alzheimer’s and observe the effects on each hallmark of Alzheimer’s disease. We will be using a magnetic resonance imaging (MRI) technique which enables the observation of some of the hallmarks non-invasively. This is important as we may gain insight into markers of Alzheimer’s disease which could be used to diagnosis and monitor disease progression. Overall, I aim to better understand the role of PLA2 in Alzheimer’s disease progression, if PLA2 activity corresponds to any key markers of disease, and if PLA2 inhibition could be therapeutic.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hiles, Emily G
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~